Skyclarys (omaveloxolone) approved as first-line treatment for rare neurodegenerative disease

Biogen recently announced that its drug Skyclarys (Omasolone) has been approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA< span>), becoming the first drug to treat Friedreich's ataxia (FA), a rare neurodegenerative disease, for people aged 16 and above. < /span>FDA approval, and will be approved for sale in the EU market in February 2024. With the approval of the drug, Skyclarys brings new hope to patients with this rare and difficult-to-treat disease.

Friedreich's ataxia (FA) is an extremely rare hereditary neuromuscular disease, mainly caused by mutations in the FXN gene encoding frataxin (frataxin protein). Studies have shown that frataxin is a mitochondrial protein that is critical for the function of multiple organs, and FA patients have significantly reduced amounts of frataxin in their cells. The loss of frataxin leaves organs such as the nervous system, heart and pancreas vulnerable to free radical damage. FAEarly symptoms include loss of coordination and muscle weakness, usually in childhood. Most patients become wheelchair dependent within 10 to 20 years after the onset of symptoms. As the disease progresses, patients may develop a series of complications such as hearing loss, visual impairment, swallowing and speech difficulties, scoliosis, diabetes, and heart disease, which will have a huge impact on the patient's quality of life.

Skyclarys was originally developed byReata Pharmaceuticals and has been acquired by Biogen. It is an orally active NRF2 activator that inhibits by activating the Nrf2 pathway. STINGdependent NF-κb signaling pathway, thereby reducing the generation of osteoclasts. The drug's specific mechanism is not fully understood, but studies have shown that it can activate Nrf2 in animals and humans in vitro and in vivo pathways, help restore mitochondrial function, reduce oxidative stress and inhibit pro-inflammatory signaling, thereby promoting inflammation resolution. The MHRA's decision to approve Skyclarys was based on positive results from the MOXIe trial, a placebo-controlled study evaluating the drug in patients with FA.

The primary endpoint of the MOXIetrial was to evaluate the modified versionFA48 >Change in score on the mFARS rating scale (mFARS), which measures disease progression in FA patients over a series of physical examinations. The results of the study showed that FA patients treated with omaveloxolone performed significantly better on the mFARS score than the placebo group. Specifically, patients in the treatment group experienced a mFARS score that decreased by 1.55 points from baseline, while those in the placebo group increased by 0.85 points. The placebo-adjusted difference between the two groups was -2.41 points, with a p value of 0.0138 showing a statistically significant difference. In the subgroup of patients with cavus cavus, omaveloxolone treatment improved mFARS scores by 1.93 points compared with placebo (p=0.034). In addition, the MOXIe open-label study further confirmed the difference between the omaveloxolone treatment group and the placebo group during the extension phase ( LSThe average difference=-2.91) was maintained, which shows that the long-term treatment effect of the drug on patients is relatively stable, and the effect is more significant for patients who receive treatment earlier.

In clinical trials,Skyclarys的常见不良反应包括肝酶升高，这可能提示药物毒性。其他副作用还包括头痛、恶心、腹痛、疲劳、腹泻和肌肉疼痛。 Although the label does not contain a boxed warning, the package insert recommends that clinicians check patients' liver enzyme levels before starting treatment and monitor these levels periodically during treatment to ensure patient safety.

Skyclarys的上市为弗里德赖希共济失调（FA）患者带来了新的治疗选择。随着药物在全球范围内的推广，未来有望为更多患者提供帮助，改善其生活质量。虽然目前该药物仍需进一步的临床监测与研究，但它无疑为这一罕见疾病的治疗开辟了新的前景。

References:Biogen’s Skyclarys granted MHRA approval for rare movement disorder Friedreich’s ataxia